EUCTR2006-007076-15-DE进行中（未招募）不适用
A Randomized Phase III Trial Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatin-Based Chemoradiotherapy with Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced Squamous Cell Cancer of the Head and Neck - The Paradigm Trial
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically proven squamous cell carcinoma of the head and neck.
- •2. Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx or larynx. Although they are admittedly of squamous cell types, the following tumors will be excluded because their responsiveness to chemotherapy may differ: tumors of the nasal and paranasal cavities and of the nasopharynx. Oral cavity tumors with mandible invasion are excluded because the tumor biology and management of these tumors is more complex and will likely include upfront surgical resection. Subjects with unknown primary sites will not be eligible for this study.
- •3. Stage 3 or 4 disease without evidence of distant metastases verified by chest X-Ray, abdominal ultrasound, PET/CT or CAT scan (liver function test abnormalities); bone scan in case of local symptoms.
- •4. At least one uni- or bidimensionally measurable lesion
- •5. No previous chemotherapy for any reason and no previous surgery for SCCHN (other than biopsy) are allowed at time of study entry (Prior tonsillectomy is allowed). No radiotherapy to the head and neck area is allowed. Patient who had radiotherapy for other cancers more than 5 years ago may be potential candidates for this trial; however each case must be discussed with the Overall PI, Dr. Robert Haddad.
- •6. Age > 18 years.
- •7. WHO performance status of 0 or 1
- •8. No active alcohol addiction that will interfere with participation in this study, as documented by the caregiver.
- •9. Signed informed consent prior to beginning protocol specific procedures.
- •10. Adequate bone marrow, hepatic and renal functions
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or breast feeding women, or women and men of childbearing potential not willing to use adequate contraception while on treatment and for at least 3 months thereafter.
- •2. Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years. Any prior treatment with chemotherapy is an exclusion criterion.
- •3. Symptomatic peripheral neuropathy > grade 2 by National Cancer Institute Common Toxicity Criteria (NCIC-CTC Version 3.0).
- •4. Symptomatic altered hearing > grade 2 by NCIC-CTC v3.0 criteria.
- •5. Other serious illnesses or medical conditions including but not limited to:
- •Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
- •History of significant neurologic or psychiatric disorders including dementia or seizures.
- •Active clinically significant uncontrolled infection.
- •Active peptic ulcer disease defined as unhealed or clinically active and clinically significant, as documented by the investigator.
- •Clinically significant hypercalcemia.
- •Active drug addiction including cocaine or intravenous drug use defined as occurring within the 6 months preceding diagnosis, which may interfere with study treatment, as documented by investigator.
- •Chronic Obstructive Pulmonary Disease, defined as being associated with a hospitalization for pneumonia or respiratory decompensation within 12 months of diagnosis. This does not include obstruction from tumor.
- •Autoimmune disease requiring therapy, prior organ transplant, or HIV infection
- •6. Patients who experienced an involuntary weight loss of more than 25% of their body weight in the 2 months preceding study entry.
- •7. Concurrent treatment with any other anticancer therapy.
- •8. Participation in an investigational trial within 30 days of study entry.
研究者
相似试验
进行中（未招募）
不适用
A Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma - PORTEC-3EUCTR2007-004917-33-ATeiden University Medical Centre800
进行中（未招募）
1 期
A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma - FEDEGYN 01/0902 - PORTEC 3Patientes atteintes d’un cancer de l’endomètre de stade avancé et à haut risque de récidive, initialement traitées par chirurgie. Carcinome de l’endomètre de stade IB grade 3 +LVSI (invasion de l’espace lympho-vasculaire), IC ou IIA grade 3, IIB, IIIA ou IIIC (les IIIA basés uniquement sur la cytologie péritonéale sont éligibles seulement si grade 3), et IB, IC, II ou III avec histologie des cellules séreuses ou claires.MedDRA version: 9.1 Level: LLT Classification code 10014738 Term: Endometrial cancer stage IMedDRA version: 9.1 Level: LLT Classification code 10014739 Term: Endometrial cancer stage IIMedDRA version: 9.1 Level: LLT Classification code 10014740 Term: Endometrial cancer stage IIIEUCTR2007-004917-33-FReiden University Medical Centre500
进行中（未招募）
不适用
A III Trial Comparing Chemotherapy and Radiotherapy against Radiotherapy alone in patients with High Risk and Advanced Uterus cancer.Endometrial carcinomaMedDRA version: 14.1Level: PTClassification code 10014740Term: Endometrial cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10014739Term: Endometrial cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10014738Term: Endometrial cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004917-33-GBeiden University Medical Centre670
招募中
3 期
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivolumab - ipilimumab in patient with stage IV lung cancer2024-514586-20-01Intergroupe Francophone De Cancerologie Thoracique1,360
招募中
3 期
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell TumorsGerm Cell TumorSeminomaChoriocarcinomaTeratomaGerminomaMixed Germ Cell TumorYolk Sac TumorChildhood TeratomaMalignant Germ Cell NeoplasmExtragonadal SeminomaNon-seminomatous Germ Cell TumorCancer - TesticularCancer - Other cancer typesCancerACTRN12618001236280Alliance for Clinical Trials in Oncology420